Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 6, 2012

FDA Sanctions Roche’s CMV Test

  • Roche’s Cobas® AmpliPrep/Cobas TaqMan® CMV test for evaluating cytomegalovirus (CMV) load received FDA premarket approval. The firm says the fully automated assay is the first FDA-approved laboratory test for use in quantifying CMV DNA in human plasma specimens. The assay is designed to aid in the management of solid organ transplant patients undergoing anti-CMV therapy by assessing virologic response to therapy.

    The real-time PCR-based test is designed for use on the Cobas AmpliPrep/Cobas TaqMan system, which can be combined with the cobas p 630 instrument to provide integrated preanalytical primary tube handling. “With this test, laboratories now have an FDA-approved option for standardized and automated CMV viral load testing that improves the laboratory workflow,” comments Paul Brown, Ph.D., head of Roche Molecular Diagnostics.

    Roche’s Cobas AmpliPrep/Cobas TaqMan system combines the Cobas AmpliPrep instrument for automated sample preparation with the Cobas TaqMan Analyzer or smaller Cobas TaqMan 48 Analyzer for automated RT-PCR. The system can be used for parallel processing of other molecular diagnostic assays for other infectious diseases. 

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »